Get 40% Off
💰 Buffett reveals a $6.7B stake in Chubb. Copy the full portfolio for FREE with InvestingPro’s Stock Ideas toolCopy Portfolio

Novartis to buy cancer drug maker MorphoSys for €2.7bn

Published 06/02/2024, 14:11
© Reuters.  Novartis to buy cancer drug maker MorphoSys for €2.7bn
MORG
-
0QLR
-

Proactive Investors - Novartis (LON:0QLR) AG has announced the acquisition of Germany-based cancer drug maker MorphoSys AG through a €2.7 billion deal.

Unveiling the takeover on Monday, Novartis said the move would expand its oncology pipeline, relating to cancer treatments, alongside widening its footprint in haematology - blood disease studies.

Novartis will pay €68 per share in the biopharmaceutical firm, marking an 18% premium on Monday’s closing price.

“We are excited about the opportunity of bringing pelabresib, a potential next-generation treatment combined with ruxolitinib, to people living with myelofibrosis, a rare and debilitating form of blood cancer,” Novartis chief medical officer Shreeram Aradhye said.

This potential rare bone marrow cancer treatment has shown favourable trends in clinical trials, Novartis pointed out in a press release, with filing to the US Food and Drug Administration (FDA) expected later this year.

Novartis’ takeover of MorphoSys follows efforts to cut costs last year as part of a wider bid to refocus on fewer markets and therapeutic areas.

The deal includes a minimum acceptance threshold of 65% of MorphoSys' share capital and is subject to regulatory approval.

Shares in MorphoSys soared 14% to €65.40 on the news.

Read more on Proactive Investors UK

Disclaimer

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.